aktiia raised CHF4m seed funding to commercialize its disruptive algorithms for blood pressure monitoring

– SWITZERLAND, Neuchâtel – aktiia, a technology company founded by leading experts from the Swiss research institute CSEM, raised CHF 4 million in seed round to commercialize its disruptive algorithms for blood pressure monitoring.

“There’s an urgent need to address the problem of hypertension, as it affects every third adult, and is the largest epidemic known to mankind. We will empower people with cutting edge technology in this fight.”, said Mattia Bertschi, co-founder and CEO.

aktiia’s technology combines common optical sensors, widely-known for tracking heart-rate in today’s wearables, and clinically validated software algorithms to measure an individual’s blood pressure at the wrist. The algorithms will be embedded in non-medical third-party wearables for preventive purpose to track blood pressure trends, as well as in aktiia’s medical grade wearable to monitor precise blood pressure values that can be used for the diagnosis and management of hypertension.

The development of aktiia’s patented technology is directed by the co-founder and CTO, Josep Sola, a pioneering expert in the field. “This technology is a quantum leap in the fight against hypertension and will revolutionize the way we look at blood pressure.” stated Michael Sidler, Co-Founder and Partner of Redalpine.

Led by the Silicon Valley based TransLink Capital, and Swiss based Redalpine, the funding will fuel aktiia in achieving its goal of getting hypertension monitors to those who need it most. The seed round also includes strategically recruited international angel investors: Christian Wenger (Switzerland), Mladen Barbaric of Pearl Studios(Canada), and Sparks Street Capital (USA), underpinning the company with a global network and commercialization experience.

“TransLink has always been on the forefront of wearable technologies, and we are constantly on the lookout for pioneers. We are very excited to be a part of what will be a healthcare game changer.” said Eric Hsia, Managing Director of TransLink Capital.

aktiia is currently developing both strategic third-party manufacturer partnerships, as well as its full product offering.

About aktiia

aktiia is a Swiss startup founded in May 2018 by Mattia Bertschi and Josep Sola. The team currently counts 10 employees and is located in Neuchatel (Switzerland) and Zürich (Switzerland). aktiia’s patented core technology for blood pressure monitoring is based on more than 15 years of pioneering work and over 30 peer-reviewed publications at the Swiss research and technology organization CSEM. aktiia’s technology combines common optical sensors and clinically validated software algorithms to measure an individual’s blood pressure at the wrist.The technology has been validated through trials in acute and low-acute settings with worldwide acknowledgement of its accuracy.

For more information : http://www.aktiia.com

About TransLink Capital

Based in Palo Alto, California, with offices in Beijing, Taipei, Tokyo and Seoul, TransLink Capital invests in technology startups that benefit from the firm’s long-standing strategic relationships with the leading Asian information technology, internet, telecommunications, and financial services corporations across Greater China, Japan, and South Korea.

For more information : http://translinkcapital.com

About Redalpine

Redalpine is a European early-stage investor, focusing on highly scalable ICT and Health-Tech ventures. Established in 2007 by a group of successful serial entrepreneurs, Redalpine empowers talented entrepreneurs to turn ambitious visions into reality by providing funding, guidance and an expansive business network.

For more information : http://www.redalpine.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.